^
    Back
    Association details:
    Biomarker:ZNF479 mutation + TMB-H
    Cancer:Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2021
    Title:

    1738P - Association of ZNF479 mutation with tumor mutation burden and survival in lung cancer patients treated with immune checkpoint inhibitors

    Published date:
    09/13/2021
    Excerpt:
    ZNF479 mutation is associated with higher TMB (p=0.044), significantly longer PFS(16.0 vs 4.2 months; HR, 0.1; P=0.006) and longer OS (23.3 vs 6.8 months; p=0.032) in lung cancer patients treated with ICIs.